Clinical trial · no report yet · Phase 3
ANVIL
Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial)
- NCT02595944 ↗
- Active not recruiting
- National Cancer Institute (NCI)
- 13 commentary sources found
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 11 | |
| Podcasts | 2 |
The trial
ClinicalTrials.gov- Official title
- Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
- Phase
- Phase 3
- Status
- Active not recruiting
- Conditions
- Stage IB Lung Non-Small Cell Carcinoma AJCC v7; Stage II Lung Non-Small Cell Cancer AJCC v7; Stage IIIA Lung Non-Small Cell Cancer AJCC v7
- Interventions
- Biospecimen Collection; Computed Tomography; Echocardiography Test; Nivolumab; Observation Activity; Positron Emission Tomography
- Arms
- Arm I (nivolumab) · Experimental
- Arm II (observation) · Active comparator
- Enrollment
- 903 (estimated)
- Primary outcomes
- Disease-free survival (DFS)
- Overall survival (OS)
- Sponsor
- National Cancer Institute (NCI)
- Start
- Jul 22, 2016
- Primary completion
- May 31, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT02595944 · updated Oct 1, 2026
Publications
linked from the registry- Chaft JE, Sun Z, Rudin CM, Khullar OV, Simone CB 2nd, Oettel K, Kozono D, Sunkara R, Faller B, Isbell JM, Hugec V, Shipstone A, McGary EC, Clarke JM, Talsania A, Ding L, Govindan R, Sands JM, Heymach JV, Raez LE, Malik SM, Stinchcombe TE, Mandrekar SJ, Bradley J, Gerber DE, Vokes E, Gandara D, Staley C, Ramalingam SS. Adjuvant Nivolumab vs Observation in Resected Non-Small Cell Lung Cancer: A Randomized Clinical Trial. JAMA. 2026 Aug 11;336(6):464-472. doi: 10.1001/jama.2026.8992. PubMed 42224490
- Frumm SM, Florez N, Lee JM, Rotow JK, Chaft JE. Updates on the Perioperative Management of Resectable Non-Small Cell Lung Cancer. J Natl Compr Canc Netw. 2026 Mar 24;24(4):e267005. doi: 10.6004/jnccn.2026.7005. PubMed 41911908